Protara Therapeutics, Inc. (TARA)
NASDAQ: TARA · IEX Real-Time Price · USD
2.230
-0.030 (-1.33%)
Jul 19, 2024, 4:00 PM EDT - Market closed
Company Description
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases.
The company’s lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.
It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition.
The company is headquartered in New York, New York.
Protara Therapeutics, Inc.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 27 |
| CEO | Jesse Shefferman |
Contact Details
Address: 345 Park Avenue South, 3rd Floor New York, New York 10010 United States | |
| Phone | 646-844-0337 |
| Website | protaratx.com |
Stock Details
| Ticker Symbol | TARA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001359931 |
| CUSIP Number | 74365U107 |
| ISIN Number | US74365U1079 |
| Employer ID | 20-4580525 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Jesse Shefferman | Co-Founder, Chief Executive Officer, President and Director |
| Dr. Jacqueline Zummo M.B.A., M.P.H., Ph.D. | Co-Founder, Senior Vice President and Chief Scientific Operations Officer |
| Dr. Jathin Bandari M.D. | Executive Officer |
| Patrick Fabbio M.B.A. | Chief Financial Officer |
| Hannah Fry | Vice President, Principal Accounting Officer and Controller |
| Justine O'Malley | Senior Vice President of Investor Relations and Corporate Affairs |
| Mary J. Grendell | General Counsel and Corporate Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 10, 2024 | 8-K | Current Report |
| May 9, 2024 | EFFECT | Notice of Effectiveness |
| May 9, 2024 | 424B3 | Prospectus |
| May 7, 2024 | UPLOAD | Filing |
| May 2, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| May 2, 2024 | 10-Q | Quarterly Report |
| May 2, 2024 | 8-K | Current Report |
| Apr 26, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 26, 2024 | ARS | Filing |
| Apr 26, 2024 | DEF 14A | Other definitive proxy statements |